MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555894 | Name: BMS-986141

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BMS-986141 is an Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4 (PRA4 antagonist), BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys. BMS-986141 inhibited platelet aggregation induced by PAR4-AP in human and monkey blood in vitro with comparable IC50of 1.8±0.3 and 1.2±0.3 nM, respectively

Chemical Structure

BMS-986141
CAS#1478711-48-6

Theoretical Analysis

MedKoo Cat#: 555894

Name: BMS-986141

CAS#: 1478711-48-6

Chemical Formula: C27H23N5O5S2

Exact Mass: 561.1141

Molecular Weight: 561.63

Elemental Analysis: C, 57.74; H, 4.13; N, 12.47; O, 14.24; S, 11.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BMS-986141; BMS 986141; BMS986141;
IUPAC/Chemical Name
4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-1,3-thiazol-2-yl]-N,N-dimethylbenzamide
InChi Key
KEEBLYWBELVGPQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H23N5O5S2/c1-31(2)25(33)16-7-5-15(6-8-16)24-28-17(14-38-24)13-36-21-9-18(34-3)10-22-19(21)11-23(37-22)20-12-32-26(29-20)39-27(30-32)35-4/h5-12,14H,13H2,1-4H3
SMILES Code
O=C(N(C)C)C1=CC=C(C2=NC(COC3=CC(OC)=CC4=C3C=C(C5=CN6C(SC(OC)=N6)=N5)O4)=CS2)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Protease-activated receptor (PAR)4 belongs to a class of G-protein coupled receptors (GPCRs) that are activated by serine proteases. PARs play important roles in hemostasis, thrombosis, inflammation, and cell proliferation. Although thrombin is the best characterized activator, PAR4 is also activated by a variety of proteases released in response to cellular injury, such as cathepsin and trypsin. PAR4 is expressed on a variety of cell types, but aside from platelets, expression tends to be low under basal conditions, and upregulated in response to cell stressors

Preparing Stock Solutions

The following data is based on the product molecular weight 561.63 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. French SL, Hamilton JR (2016) Protease-activated receptor 4: from structure to function and back again. Br J Pharmacol 173, 2952-2965.https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.13455 2. Fender AC, Rauch BH, Geisler T et al. (2017) Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation? Thromb Haemost 117, 2013-2025.https://www.ncbi.nlm.nih.gov/pubmed/29044290 3. Li S, Tarlac V, Hamilton JR (2019) Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When? International Journal of Molecular Sciences 20, 5629.https://www.mdpi.com/1422-0067/20/22/5629 4. Rohatgi T, Sedehizade F, Reymann KG et al. (2004) Protease-Activated Receptors in Neuronal Development, Neurodegeneration, and Neuroprotection: Thrombin as Signaling Molecule in the Brain. The Neuroscientist 10, 501-512.https://journals.sagepub.com/doi/abs/10.1177/1073858404269955 5. De Luca C, Colangelo AM, Alberghina L et al. (2018) Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. Front Cell Neurosci 12, 459-459.https://www.ncbi.nlm.nih.gov/pubmed/30534057 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275309/ 6. Yin X, Wright J, Wall T et al. (2010) Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol 176, 1600-1606.https://www.ncbi.nlm.nih.gov/pubmed/20150433 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2843451/ 7. Suo Z, Wu M, Citron BA et al. (2003) Persistent Protease-activated Receptor 4 Signaling Mediates Thrombin-induced Microglial Activation. Journal of Biological Chemistry 278, 31177-31183.http://www.jbc.org/content/278/33/31177.abstract 8. Espinosa-Parrilla Y, Gonzalez-Billault C, Fuentes E et al. (2019) Decoding the Role of Platelets and Related MicroRNAs in Aging and Neurodegenerative Disorders. Front Aging Neurosci 11, 151-151.https://www.ncbi.nlm.nih.gov/pubmed/31312134 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614495/ 9. Prodan CI, Ross ED, Vincent AS et al. (2008) Rate of progression in Alzheimer’s disease correlates with coated-platelet levels—a longitudinal study. Translational Research 152, 99-102.http://www.sciencedirect.com/science/article/pii/S1931524408001874 10. Edelstein LC, Simon LM, Lindsay CR et al. (2014) Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124, 3450-3458.https://www.ncbi.nlm.nih.gov/pubmed/25293779 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246040/ 11. Whitley MJ, Henke DM, Ghazi A et al. (2018) The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y(12) inhibition. J Thromb Haemost 16, 2501-2514.https://www.ncbi.nlm.nih.gov/pubmed/30347494 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289679/ 12. Mao Y, Zhang M, Tuma RF et al. (2010) Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab 30, 1044-1052.https://www.ncbi.nlm.nih.gov/pubmed/20087365 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2949190/ 13. Wong PC, Seiffert D, Bird JE et al. (2017) Blockade of protease-activated receptor-4 (PAR4) provides robust antithrombotic activity with low bleeding. Science Translational Medicine 9, eaaf5294.https://stm.sciencemag.org/content/scitransmed/9/371/eaaf5294.full.pdf 14. Wong PC, Watson CA, Bostwick J et al. (2017) Abstract 13794: An Orally-Active Small-Molecule Antagonist of the Platelet Protease-Activated Receptor-4, BMS-986141, Prevents Aeterial Thrombosis With Low Bleeding Liability in Cynomolgus Monkeys. Circulation 136, A13794-A13794.https://ahajournals.org/doi/abs/10.1161/circ.136.suppl_1.13794 15. Ismat FA, Ma X, Wang Z et al. (2016) Abstract TMP91: Phase I Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Oral Protease-activated Receptor-4 Antagonist BMS-986120. Stroke 47, ATMP91-ATMP91.https://www.ahajournals.org/doi/abs/10.1161/str.47.suppl_1.tmp91 16. Wilson SJ, Ismat FA, Wang Z et al. (2018) PAR4 (Protease-Activated Receptor 4) Antagonism With BMS-986120 Inhibits Human Ex Vivo Thrombus Formation. Arterioscler Thromb Vasc Biol 38, 448-456.https://www.ncbi.nlm.nih.gov/pubmed/29269513 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779320/ 17. Casa LDC, Deaton DH, Ku DN (2015) Role of high shear rate in thrombosis. Journal of Vascular Surgery 61, 1068-1080.http://www.sciencedirect.com/science/article/pii/S0741521415000221 18. Callejo MF, Colin J, Desmeules S et al. (2016) Abstract WP263: Mutagenesis Studies Revealed Minimal Impact of Human A120T Variant of Protease-activated Receptor 4 on Receptor function or Pharmacological Response to a Potent and Selective Antagonist. Stroke 47, AWP263-AWP263.https://www.ahajournals.org/doi/abs/10.1161/str.47.suppl_1.wp263 19. Miao X, Zhang W, Huang Z et al. (2016) Unaltered Angiogenesis-Regulating Activities of Platelets in Mild Type 2 Diabetes Mellitus despite a Marked Platelet Hyperreactivity. PLOS ONE 11, e0162405.https://doi.org/10.1371/journal.pone.0162405 20. Dangwal S, Rauch BH, Gensch T et al. (2011) High Glucose Enhances Thrombin Responses via Protease-Activated Receptor-4 in Human Vascular Smooth Muscle Cells. Arterioscler Thromb Vasc Biol 31, 624-633.https://www.ahajournals.org/doi/abs/10.1161/ATVBAHA.110.219105 21. Fender AC, Kleeschulte S, Stolte S et al. (2020) Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. Basic Research in Cardiology 115, 10.https://doi.org/10.1007/s00395-019-0771-9 22. Rigg RA, Healy LD, Chu TT et al. (2019) Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets 30, 126-135.https://www.ncbi.nlm.nih.gov/pubmed/30560697 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397092/ 23. Han N, Jin K, He K et al. (2011) Protease-activated receptors in cancer: A systematic review. Oncol Lett 2, 599-608.https://www.ncbi.nlm.nih.gov/pubmed/22848234 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406414/ 24. Ma L, Perini R, McKnight W et al. (2005) Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proceedings of the National Academy of Sciences of the United States of America 102, 216-220.https://www.pnas.org/content/pnas/102/1/216.full.pdf 25. Italiano JE, Jr., Richardson JL, Patel-Hett S et al. (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111, 1227-1233.https://www.ncbi.nlm.nih.gov/pubmed/17962514 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214735/ 26. Liu X, Yu J, Song S et al. (2017) Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer. Oncotarget 8, 107334-107345.https://www.ncbi.nlm.nih.gov/pubmed/29291033 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739818/ 27. Zhang H, Jiang P, Zhang C et al. (2018) PAR4 overexpression promotes colorectal cancer cell proliferation and migration. Oncol Lett 16, 5745-5752.https://www.ncbi.nlm.nih.gov/pubmed/30333860 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176407/ 28. Jiang P, De Li S, Li ZG et al. (2018) The expression of protease-activated receptors in esophageal carcinoma cells: the relationship between changes in gene expression and cell proliferation, apoptosis in vitro and growing ability in vivo. Cancer Cell International 18, 81.https://doi.org/10.1186/s12935-018-0577-0 29. Sheth RA, Niekamp A, Quencer KB et al. (2017) Thrombosis in cancer patients: etiology, incidence, and management. Cardiovasc Diagn Ther 7, S178-S185.https://www.ncbi.nlm.nih.gov/pubmed/29399521 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778519/ 30. Sharma BK, Flick MJ, Palumbo JS (2019) Cancer-Associated Thrombosis: A Two-Way Street. Semin Thromb Hemost 45, 559-568.https://www.ncbi.nlm.nih.gov/pubmed/31382306 31. Holmes CE, Levis JE, Schneider DJ et al. (2016) Platelet phenotype changes associated with breast cancer and its treatment. Platelets 27, 703-711.https://doi.org/10.3109/09537104.2016.1171302 .